Difference between revisions of "Bladder cancer - historical"
Jump to navigation
Jump to search
(Jwarner moved page Bladder cancer - historical to Urothelial carcinoma - historical) Tag: New redirect |
m (Removed redirect to Urothelial carcinoma - historical) Tag: Removed redirect |
||
Line 1: | Line 1: | ||
− | # | + | <span id="BackToTop"></span> |
+ | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
+ | [[#top|Back to Top]] | ||
+ | </div> | ||
+ | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Bladder cancer|main bladder cancer page]] for current regimens. | ||
+ | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
+ | |- | ||
+ | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | ||
+ | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
+ | |} | ||
+ | {{TOC limit|limit=3}} | ||
+ | |||
+ | =Nonmuscle invasive bladder cancer= | ||
+ | ==Intravesicular Doxorubicin monotherapy {{#subobject:8034b6|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:49ccdb|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | | rowspan="2" |[https://doi.org/10.1016/s0022-5347(17)40002-4 Martínez-Piñeiro et al. 1990] | ||
+ | | rowspan="2" |1980-1988 | ||
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1. [[Bladder_cancer#Bacillus_Calmette-Guérin_.28BCG.29_monotherapy|BCG]] | ||
+ | | style="background-color:#d73027" |Inferior RFS | ||
+ | |- | ||
+ | |2. [[Bladder_cancer#Intravesicular_Thiotepa_monotherapy|Thiotepa]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/NEJM199110243251703 Lamm et al. 1991 (SWOG 8216)] | ||
+ | |1983-1985 | ||
+ | | style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |[[Bladder_cancer#Bacillus_Calmette-Guérin_.28BCG.29_monotherapy|BCG]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior DFS | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Doxorubicin (Adriamycin)]] 50 mg intravesicularly once on day 1 | ||
+ | '''7-day cycle for 5 cycles, then 30-day cycle for 11 cycles (approximately 1 year)''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. [https://doi.org/10.1016/s0022-5347(17)40002-4 link to original article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/2106041/ PubMed] | ||
+ | #'''SWOG 8216:''' Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. [https://doi.org/10.1056/NEJM199110243251703 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/1922207/ PubMed] | ||
+ | ==Intravesicular Thiotepa monotherapy {{#subobject:5b9d6c|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:97d2e7|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Dates of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | | rowspan="2" |[https://doi.org/10.1016/s0022-5347(17)40002-4 Martínez-Piñeiro et al. 1990] | ||
+ | | rowspan="2" |1980-1988 | ||
+ | | rowspan="2" style="background-color:#1a9851" |Phase 3 (C) | ||
+ | |1. [[Bladder_cancer#Bacillus_Calmette-Guérin_.28BCG.29_monotherapy|BCG]] | ||
+ | | style="background-color:#d73027" |Inferior RFS | ||
+ | |- | ||
+ | |2. [[#Intravesicular_Doxorubicin_monotherapy|Doxorubicin]] | ||
+ | | style="background-color:#d3d3d3" |Not reported | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Thiotepa (Thioplex)]] 50 mg intravesicularly x 15 treatments | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. [https://doi.org/10.1016/s0022-5347(17)40002-4 link to original article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/2106041/ PubMed] | ||
+ | [[Category:Bladder cancer regimens]] | ||
+ | [[Category:Historical regimens]] | ||
+ | [[Category:Disease-specific pages]] | ||
+ | [[Category:Urothelial carcinomas]] |
Revision as of 23:54, 9 September 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main bladder cancer page for current regimens.
2 regimens on this page
2 variants on this page
|
Nonmuscle invasive bladder cancer
Intravesicular Doxorubicin monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Martínez-Piñeiro et al. 1990 | 1980-1988 | Phase 3 (C) | 1. BCG | Inferior RFS |
2. Thiotepa | Not reported | |||
Lamm et al. 1991 (SWOG 8216) | 1983-1985 | Phase 3 (C) | BCG | Seems to have inferior DFS |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg intravesicularly once on day 1
7-day cycle for 5 cycles, then 30-day cycle for 11 cycles (approximately 1 year)
References
- Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed
- SWOG 8216: Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. link to original article contains dosing details in manuscript PubMed
Intravesicular Thiotepa monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Martínez-Piñeiro et al. 1990 | 1980-1988 | Phase 3 (C) | 1. BCG | Inferior RFS |
2. Doxorubicin | Not reported |
Chemotherapy
- Thiotepa (Thioplex) 50 mg intravesicularly x 15 treatments
References
- Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed